{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:45:17Z","timestamp":1790729117393,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-03335-1","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T21:53:18Z","timestamp":1738965198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are EGFR monoclonal antibodies associated with clinical benefits in patients with glioma: a systematic review, meta-analysis, and specific analysis on glioblastoma and diffuse intrinsic pontine glioma"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5752","authenticated-orcid":false,"given":"Farhang","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-4764","authenticated-orcid":false,"given":"Hossein","family":"Gharedaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7511-1601","authenticated-orcid":false,"given":"Sahar","family":"Fathi Tavani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1715-8490","authenticated-orcid":false,"given":"Hossein","family":"Farzalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahir Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0521-8420","authenticated-orcid":false,"given":"Amirmohammad","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-0778","authenticated-orcid":false,"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Hajikarimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"6","key":"3335_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.bmt.1705454","volume":"38","author":"D Wolff","year":"2006","unstructured":"Wolff D et al (2006) Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 38(6):445\u2013451","journal-title":"Bone Marrow Transplant"},{"key":"3335_CR2","doi-asserted-by":"crossref","unstructured":"Weller M et al (2015) Glioma Nat Rev Dis Primers 1:15017","DOI":"10.1038\/nrdp.2015.17"},{"issue":"1","key":"3335_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","volume":"40","author":"NA Bush","year":"2017","unstructured":"Bush NA, Chang SM, Berger MS (2017) Current and future strategies for treatment of glioma. Neurosurg Rev 40(1):1\u201314","journal-title":"Neurosurg Rev"},{"issue":"1","key":"3335_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98\u2013110","journal-title":"Cancer Cell"},{"key":"3335_CR5","doi-asserted-by":"crossref","unstructured":"Oprita A et al (2021) Updated insights on EGFR Signaling pathways in Glioma. Int J Mol Sci, 22(2)","DOI":"10.3390\/ijms22020587"},{"issue":"12","key":"3335_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008209720526","volume":"8","author":"BR Voldborg","year":"1997","unstructured":"Voldborg BR et al (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197\u20131206","journal-title":"Ann Oncol"},{"issue":"12","key":"3335_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3390\/biology11121767","volume":"11","author":"MA Habibi","year":"2022","unstructured":"Habibi MA et al (2022) The efficacy and safety of Rituximab in ANCA-Associated Vasculitis: a systematic review. Biology 11(12):1767","journal-title":"Biology"},{"key":"3335_CR8","doi-asserted-by":"crossref","unstructured":"Habibi MA et al (2024) The safety and efficacy of dabrafenib and trametinib in patients with glioma: a systematic review and meta-analysis. Eur J Clin Pharmacol","DOI":"10.1007\/s00228-024-03635-3"},{"key":"3335_CR9","doi-asserted-by":"publisher","first-page":"994726","DOI":"10.3389\/fonc.2022.994726","volume":"12","author":"Y Yuan","year":"2022","unstructured":"Yuan Y et al (2022) Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: a meta-analysis of randomized controlled trials. Front Oncol 12:994726","journal-title":"Front Oncol"},{"issue":"4","key":"3335_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14712598.2018.1452906","volume":"18","author":"L Mazzarella","year":"2018","unstructured":"Mazzarella L, Guida A, Curigliano G (2018) Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther 18(4):483\u2013493","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"3335_CR11","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.3748\/wjg.v21.i22.7022","volume":"21","author":"XX Li","year":"2015","unstructured":"Li XX et al (2015) Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol 21(22):7022\u20137035","journal-title":"World J Gastroenterol"},{"key":"3335_CR12","doi-asserted-by":"crossref","unstructured":"Kast J, Dutta S, Upreti VV, Panitumumab (2021) A review of clinical pharmacokinetic and Pharmacology Properties after over a decade of experience in patients with solid tumors. Adv Ther 38(7):3712\u20133723","DOI":"10.1007\/s12325-021-01809-4"},{"issue":"5","key":"3335_CR13","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2741\/3834","volume":"16","author":"AE Quatrale","year":"2011","unstructured":"Quatrale AE et al (2011) Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed) 16(5):1973\u20131985","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3335_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3335_CR15","doi-asserted-by":"crossref","unstructured":"Deeks JJ et al (2019) Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions. 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"issue":"suppl4","key":"3335_CR16","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT et al (2018) Statistical report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol 20(suppl4):iv1\u2013iv86","journal-title":"Neuro Oncol"},{"issue":"1","key":"3335_CR17","doi-asserted-by":"publisher","first-page":"i64","DOI":"10.1093\/annonc\/mdi834","volume":"16","author":"R Stupp","year":"2005","unstructured":"Stupp R, Pavlidis N, Jelic S (2005) ESMO Minimum Clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16(1):i64\u2013i65","journal-title":"Ann Oncol"},{"issue":"3","key":"3335_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/cells10030484","volume":"10","author":"A Goenka","year":"2021","unstructured":"Goenka A et al (2021) The many facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. Cells 10(3):484","journal-title":"Cells"},{"issue":"21","key":"3335_CR19","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/cancers14215377","volume":"14","author":"K Szklener","year":"2022","unstructured":"Szklener K et al (2022) New directions in the therapy of glioblastoma. Cancers 14(21):5377","journal-title":"Cancers"},{"issue":"5","key":"3335_CR20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20(5):S2","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"3335_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC et al (2020) Management of glioblastoma: state of the art and future directions. Cancer J Clin 70(4):299\u2013312","journal-title":"Cancer J Clin"},{"key":"3335_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52\u201379","journal-title":"Eur J Pharm Biopharm"},{"key":"3335_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11060-015-1920-0","volume":"125","author":"W Wei","year":"2015","unstructured":"Wei W et al (2015) The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. J Neurooncol 125:339\u2013349","journal-title":"J Neurooncol"},{"issue":"12","key":"3335_CR24","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E et al (2023) Dabrafenib plus Trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108\u20131120","journal-title":"N Engl J Med"},{"issue":"3","key":"3335_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/neuonc\/noaa240","volume":"23","author":"MR Gilbert","year":"2021","unstructured":"Gilbert MR et al (2021) A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol 23(3):468\u2013477","journal-title":"Neuro Oncol"},{"issue":"16","key":"3335_CR26","doi-asserted-by":"publisher","first-page":"8835","DOI":"10.3390\/ijms23168835","volume":"23","author":"H Sareen","year":"2022","unstructured":"Sareen H et al (2022) Molecular biomarkers in glioblastoma: a systematic review and meta-analysis. Int J Mol Sci 23(16):8835","journal-title":"Int J Mol Sci"},{"issue":"29","key":"3335_CR27","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK et al (2020) Ivosidenib in isocitrate dehydrogenase 1\u2013mutated advanced glioma. J Clin Oncol 38(29):3398","journal-title":"J Clin Oncol"},{"issue":"1","key":"3335_CR28","first-page":"47","volume":"9","author":"DE Gerber","year":"2007","unstructured":"Gerber DE et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neurooncology 9(1):47\u201352","journal-title":"Neurooncology"},{"key":"3335_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","volume":"151","author":"KM Hotchkiss","year":"2021","unstructured":"Hotchkiss KM, Sampson JH (2021) Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J Neurooncol 151:55\u201362","journal-title":"J Neurooncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-03335-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:20:24Z","timestamp":1772079624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-03335-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3335"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-03335-1","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed exempt from receiving ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}